A U.S. jury awarded Nektar Therapeutics $90 million plus interest in its lawsuit against Eli Lilly over a fractured licensing deal tied to rezpegaldesleukin (rezpeg). The ruling, issued in the U.S. District Court, found Lilly breached the implied covenant of good faith and fair dealing. While the damages are far below the amount Nektar sought, the verdict is a notable win for the biotech in a high-profile case affecting economics and trust around co-development commitments. The dispute originated from alleged failures in how Lilly and Nektar handled collaborative development expectations. The outcome may influence how biotech companies structure and enforce collaborative terms when partners control downstream development and commercialization decisions.